Top of page
Lawyers

Serdar Inci

Lawyers
Associate in our Corporate practice, based in London.

Serdar’s practice focuses on advising corporate and investment banking clients on strategic corporate transactions and international securities offerings of both debt and equity. These include initial public offerings, follow-on offerings and other SEC registered deals, Rule 144A and Regulation S transactions and other private placements.

Languages
French
German
Turkish
Languages
French
German
Turkish

Experience highlights

Since joining Davis Polk in 2018, Serdar has advised clients on a broad range of capital markets transactions, including:

Debt

Issuers

  • A leading U.K. medical technology company on its SEC-registered $1.0 billion notes offering
  • Ferguson on its $600 million Rule 144A and Reg. S notes offering
  • A leading German automobile manufacturer on various Rule 144A and Reg. S notes offerings, totaling U.S. $9 billion
  • The investment banking arm of a Scottish bank on the establishment of its $5 billion U.S. commercial paper program
  • A Swiss multinational healthcare company on the update of its $7.5 billion U.S. commercial paper program

Underwriters/Initial Purchasers

  • The initial purchasers on Anglo American's $1.0 billion Rule 144 and Reg. S notes offering
  • The initial purchasers on Fresenius Medical Care's $1.0 billion Rule 144A and Reg. S notes offering
  • The underwriters on Deutsche Bank's $500 million SEC-registered offering of subordinated Tier 2 notes
  • The underwriters on British American Tobacco's SEC-registered $2.4 billion notes offering
  • The underwriters on Oesterreichische Kontrollbank’s SEC-registered $1.5 billion notes offering
  • The underwriters on the $1.25 billion SEC-registered additional tier 1 notes offering by the largest bank in Germany
IPOs and other Equity Offerings

Issuers

  • Oncopeptides on its SEK 1.1 billion (approx. $130 million) private placement of new shares
  • Centogene on its $49 million follow-on offering
  • EQT on its $1.4 billion initial public offering on Nasdaq Stockholm
  • Xspray Pharma on its SEK 265 million private placement of new shares
  • SEAS-NVE on its DKK 5.4 billion (approx. $800 million) secondary block sale of shares in Ørsted
  • Centogene on its $56 million initial public offering on Nasdaq

Underwriters

  • The underwriters on Levere Holdings Corp.'s $250 million initial public offering
Liability Management Transactions
  • NatWest Group plc’s $1.9 billion cash tender offer
View all experience
Education
LL.M., Columbia Law School
  • DAAD Scholarship
  • Dr. Theo Waigel Scholarship
  • Dr. Walter Oppenhoff Scholarship
  • Senior Editor, Columbia Journal of European Law
Ph.D., University of Cologne
  • Ph.D. Scholarship
  • Studienstiftung Scholarship
  • summa cum laude
  • Editor-In-Chief, Cologne Business Law Review
J.D., University of Cologne
  • Dean's Award for Academic Excellence
  • Third in Class
Professional history
  • Davis Polk since 2018
Back to top